Weil Advises Blackstone in its Acquisition of a Majority Stake in ZO Skin Health, Inc.

Weil is advising Blackstone in its acquisition of a majority stake in ZO Skin Health, Inc., a manufacturer of a comprehensive suite of products designed to restore skin to a healthy state, from Dr. Zein Obagi, founder of ZO, Obagi family trusts, and Rohto Pharmaceuticals Co., Ltd., a manufacturer and marketer of pharmaceutical and cosmetic products, including eyewash, bath soaps, gastrointestinal medicine and hand cream. Terms of the transaction have not been disclosed.

The Weil team advising Blackstone is led by Private Equity partner Christopher Machera and includes Private Equity associates Brittany ButwinJenna McBainBrian Howton and Lauren Burgos (Not Yet Admitted in New York). The team also includes Tax partner Mark Schwed; Tax associate Jake Gerrit Meninga; Executive Compensation & Benefits partner Amy Rubin; Executive Compensation & Benefits associates Amanda RosenblumEmily Gulyako and Manleen Singh (Admitted in Illinois Only); Technology & IP Transactions partner Jeff Osterman; Technology & IP Transactions counsel Marisa Geiger; Technology & IP Transactions associates Rami Sherman and Meggin Bednarczyk; Cybersecurity, Data Privacy & Information Management associate Robert Brown; Real Estate partner Beatriz Azcuy; Regulatory counsel John O’Loughlin; Antitrust partner Michael Naughton; International Arbitration & Trade associate Nathan Cunningham; Employment Litigation practice Head Gary Friedman; Employment Litigation partner Nicholas Pappas; Complex Commercial Litigation partner Jessica Falk; Complex Commercial Litigation associate Hira Baig (Not Yet Admitted in New York); Employment Litigation associate Omar Abdel-Hamid (Not Yet Admitted in New York); and White Collar Defense, Regulatory and Investigations partner Holly Loiseau.